TC
MGNX icon

Truvestments Capital’s MacroGenics MGNX Stock Holding History

Truvestments Capital’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-160
Closed -$462 – 1232
2026
Q1 		$462 Sell
160
-848
-84% -$1.81K ﹤0.01% 1093
2025
Q4 		$1.62K Hold
1,008
– – ﹤0.01% 894
2025
Q3 		$1.69K Sell
1,008
-1,390
-58% -$2.25K ﹤0.01% 933
2025
Q2 		$2.9K Hold
2,398
– – ﹤0.01% 797
2025
Q1 		$3.04K Sell
2,398
-491
-17% -$1.28K ﹤0.01% 816
2024
Q4 		$9.39K Buy
2,889
+1,861
+181% +$6.7K ﹤0.01% 617
2024
Q3 		$3.38K Buy
+1,028
New +$4K ﹤0.01% 731

Other funds holding MGNX

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Truvestments Capital's MGNX Position: Q2 2026 in Review

Truvestments Capital sold out of MacroGenics (MGNX) in Q2 2026, closing a stake of 160 shares — an estimated $462 sold.

Truvestments Capital first reported a position in MGNX in Q3 2024 and held it in 7 quarters. The position peaked at $9.39K in Q4 2024. 122 funds tracked by Wall St. Rank hold MGNX as of Q2 2026.

  • Truvestments Capital reported no remaining MacroGenics position as of Q2 2026 after selling out during the quarter.
  • Truvestments Capital sold 160 MacroGenics shares in Q2 2026, an estimated $462.
  • Truvestments Capital first reported a position in MacroGenics in Q3 2024 and held it in 7 quarters.
  • Truvestments Capital's MacroGenics position peaked at $9.39K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held MacroGenics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.